Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
Cannabinoids act at two classical cannabinoid receptors (CB1 and CB2), a 7TM orphan receptor and the transmitter-gated channel transient receptor potential vanilloid type-1 receptor. Recent evidence also points to cannabinoids acting at members of the nuclear receptor family, peroxisome proliferator-activated receptors (PPARs, with three subtypes alpha, beta (delta) and gamma), which regulate cell differentiation and lipid metabolism. Much evidence now suggests that endocannabinoids are natural activators of PPAR alpha. Oleoylethanolamide regulates feeding and body weight, stimulates fat utilization and has neuroprotective effects mediated through activation of PPAR alpha. Similarly, palmitoylethanolamide regulates feeding and lipid metabolism and has anti-inflammatory properties mediated by PPAR alpha. Other endocannabinoids that activate PPAR alpha include anandamide, virodhamine and noladin. Some (but not all) endocannabinoids also activate PPAR gamma; anandamide and 2-arachidonoylglycerol have anti-inflammatory properties mediated by PPAR gamma. Similarly, ajulemic acid, a structural analogue of a metabolite of Delta(9)-tetrahydrocannabinol (THC), causes anti-inflammatory effects in vivo through PPAR gamma. THC also activates PPAR gamma, leading to a time-dependent vasorelaxation in isolated arteries. Other cannabinoids which activate PPAR gamma include N-arachidonoyl-dopamine, HU210, WIN55212-2 and CP55940. In contrast, little research has been carried out on the effects of cannabinoids at PPAR delta. In this newly emerging area, a number of research questions remain unanswered; for example, why do cannabinoids activate some isoforms and not others? How much of the chronic effects of cannabinoids are through activation of nuclear receptors? And importantly, do cannabinoids confer the same neuro- and cardioprotective benefits as other PPAR alpha and PPAR gamma agonists? This review will summarize the published literature implicating cannabinoid-mediated PPAR effects and discuss the implications thereof.
O'Sullivan
S E
SE
School of Biomedical Sciences, University of Notttingham, Queen's Medical Center, Nottingham, UK. saoirse.o'sullivan@nottingham.ac.uk
D000818:Animals; D002186:Cannabinoids / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008024:Ligands; D008954:Models, Biological; D015394:Molecular Structure; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000378:metabolism
D002186:Cannabinoids; D008024:Ligands; D047492:Peroxisome Proliferator-Activated Receptors
Int J Cancer. 2003 Mar 10;104(1):12-8
12532414
Curr Opin Pharmacol. 2003 Apr;3(2):186-91
12681242
J Clin Endocrinol Metab. 2006 Aug;91(8):3171-80
16684820
Anal Biochem. 2005 Sep 1;344(1):8-15
16038868
Eur J Pharmacol. 2007 Jul 2;566(1-3):117-9
17434479
Am J Physiol Cell Physiol. 2005 Apr;288(4):C899-905
15590897
Biochem Soc Trans. 2006 Dec;34(Pt 6):1095-7
17073758
J Pharmacol Exp Ther. 2006 Aug;318(2):563-70
16702440
Cell Mol Life Sci. 2007 Jan;64(2):219-29
17187172
J Clin Invest. 2006 Mar;116(3):556-60
16511587
Biochim Biophys Acta. 2007 Aug;1771(8):1094-107
17459763
Trends Pharmacol Sci. 2004 Jun;25(6):331-6
15165749
Diabetes. 2004 Feb;53 Suppl 1:S43-50
14749265
Mol Pharmacol. 2003 May;63(5):983-92
12695526
Eur J Pharmacol. 2005 Jul 11;517(3):174-81
15987634
J Biol Chem. 2007 Jun 22;282(25):18625-33
17462987
Mol Pharmacol. 2006 Jul;70(1):101-11
16611855
J Biol Chem. 2004 Jul 2;279(27):27849-54
15123613
Br J Pharmacol. 2000 Mar;129(5):823-34
10696077
Cell Mol Life Sci. 2007 Jun;64(11):1403-18
17447008
Nature. 2003 Sep 4;425(6953):90-3
12955147
J Biol Chem. 2002 Jun 28;277(26):23278-86
11956198
Neuroscience. 2004;123(1):131-45
14667448
J Clin Invest. 2006 Mar;116(3):590-7
16511591
Life Sci. 2006 Jan 2;78(6):549-63
16109430
PPAR Res. 2007;2007:95974
17389767
J Pharmacol Exp Ther. 2006 Apr;317(1):428-38
16352700
Circ Res. 2007 May 25;100(10):1442-51
17463321
Biochem Biophys Res Commun. 2005 Nov 25;337(3):824-31
16213464
J Pharmacol Exp Ther. 2004 Nov;311(2):683-90
15284281
Lancet. 2007 Feb 17;369(9561):555
17307094
J Neurochem. 2005 May;93(4):984-91
15857401
J Biol Chem. 2002 Nov 1;277(44):41925-30
12200443
Expert Opin Investig Drugs. 2005 Jun;14(6):557-68
16004588
Neuroscience. 2005;130(2):325-37
15664689
Diabetes. 1997 Aug;46(8):1319-27
9231657
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23
9113987
Neuropharmacology. 2008 Jan;54(1):226-34
17467748
Mol Pharmacol. 2005 Jan;67(1):15-9
15465922
J Pharmacol Exp Ther. 2006 Dec;319(3):1051-61
16997973
Curr Opin Pharmacol. 2006 Dec;6(6):606-14
16973418
Biochem Biophys Res Commun. 2007 Mar 9;354(2):427-33
17223076